Wells Fargo lowered the firm’s price target on Baxter to $44 from $46 and keeps an Equal Weight rating on the shares. Baxter’s Q2 results were ahead of expectations on broad-based strength, but uncertainty on Novum IQ approval remains an overhang, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BAX: